Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China Traditional Chinese Medicine Holdings Co ( (HK:0570) ) has issued an update.
China Traditional Chinese Medicine Holdings Co. Limited announced that the National Medical Products Administration of China has accepted the new drug application for Yushuda Tablets, an innovative traditional Chinese medicine developed by its subsidiary, Sinopharm Group Tongjitang Pharmaceutical. Yushuda Tablets have shown significant efficacy in treating mild-to-moderate depression, particularly symptoms related to qi stagnation. The acceptance marks a critical step in the regulatory process, although the timeline for approval remains uncertain, and the company advises caution to shareholders and investors.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
More about China Traditional Chinese Medicine Holdings Co
China Traditional Chinese Medicine Holdings Co. Limited operates in the traditional Chinese medicine industry, focusing on the development and production of innovative traditional Chinese medicinal products. The company is involved in creating treatments that address various health issues, with a market focus on traditional Chinese medicine.
Average Trading Volume: 28,127,140
Technical Sentiment Signal: Sell
Current Market Cap: HK$11.13B
See more data about 0570 stock on TipRanks’ Stock Analysis page.